Benefits
Increased blood and tissue glutathione levels
A 6-month RCT demonstrated Setria (250 and 1,000 mg/day) significantly increased glutathione levels in red blood cells, plasma lymphocytes, and buccal cells vs. placebo — with 30–35% increases in whole blood GSH at 6 months. Previous skepticism about oral GSH bioavailability is now addressed by this data.
Immune system enhancement
Human clinical trial showed Setria significantly increased NK cell cytotoxicity and reduced immunosuppression markers after 3 months. Higher GSH levels in immune cells support their proliferation, activity, and resistance to oxidative damage during immune responses.
Oxidative stress reduction
Glutathione is the body's primary intracellular antioxidant — present at millimolar concentrations in most cells. Supplementing Setria reduces systemic oxidative stress markers (8-OHdG, TBARS) and protects cellular proteins, DNA, and lipids from reactive oxygen species damage.
Skin Health (Trends — Not Statistically Significant in Primary RCT)
RCT in 57 Thai women showed TRENDS favoring Setria for melanin index reduction over 12 weeks, but primary endpoint did NOT reach statistical significance. The Filipino trial (open-label, single-arm) showed effects but lacked placebo control. Skin lightening is a controversial cosmetic application; marketing claims often exceed peer-reviewed evidence.
Mechanism of action
Direct cellular antioxidant activity
Glutathione (γ-glutamyl-cysteinyl-glycine) donates electrons to neutralize hydrogen peroxide, lipid peroxides, and reactive oxygen species via glutathione peroxidase (GPx) enzymes. The resulting oxidized glutathione (GSSG) is regenerated back to GSH by glutathione reductase using NADPH.
Phase II detoxification conjugation
Glutathione S-transferase enzymes conjugate GSH to electrophilic toxins, heavy metals, drug metabolites, and reactive compounds — neutralizing them and enabling urinary or biliary excretion. This is the liver's primary detoxification mechanism for xenobiotics.
Tyrosinase inhibition (skin lightening)
Glutathione inhibits tyrosinase, the rate-limiting enzyme in melanin biosynthesis, and shifts melanin production from darker eumelanin toward lighter phaeomelanin — producing the skin-lightening effects observed in clinical trials without the toxicity of chemical skin-lightening agents.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Setria® (250 mg/day and 1,000 mg/day) vs placebo in 54 healthy adults for 6 months. Outcomes: glutathione in whole blood, erythrocytes, plasma, lymphocytes. (Richie et al. 2015, Eur J Nutr)
54 healthy adults. 6-month intervention.
Both Setria® doses increased glutathione in whole blood (~+35%), erythrocytes, plasma, lymphocytes vs placebo. Industry-funded (Kyowa Hakko). IMPORTANT: this contradicts long-standing claim that oral glutathione is destroyed in GI tract; suggests Setria® form may have unique bioavailability characteristics.
Randomized double-blind placebo-controlled trial of 250 mg/day Setria reduced glutathione, 250 mg/day AquaGluta oxidized glutathione, or placebo for 12 weeks. Published Clinical, Cosmetic and Investigational Dermatology 2017.
57 healthy Thai female subjects, ages 20-50 (NOT Filipino — corrected from earlier database error).
Trends favored both glutathione forms for melanin index reduction and UV spots vs placebo, but primary endpoint did NOT reach statistical significance per published paper. Glutathione groups had higher skin elasticity (also non-significant). Industry-funded (Kyowa Hakko). CRITICAL CONTEXT: skin lightening is a controversial cosmetic application with cultural, ethical, and dermatological considerations. Press releases and marketing materials overstated significance vs published peer-reviewed results.